AxoGen, Inc. to be featured on “Living Better with Laura Smith” on ABC Radio
Interview Airs June 27th Hosted by Laura Smith, 5:15pm ET
ALACHUA, FL, June 26, 2015 – AxoGen, Inc. (NASDAQ: AXGN), a leading medical technology company dedicated to peripheral nerve repair, announced today that ABC Radio’s “Living Better with Laura Smith” will be featuring a special interview with Karen Zaderej, CEO of AxoGen. Ms. Zaderej will discuss the risk of nerve injuries in wisdom tooth removal and their symptoms.
All shareholders, analysts, industry professionals, health care providers and anyone experiencing symptoms of a nerve injury are encouraged to listen to the broadcast to learn more about options in nerve repair. Broadcast details for the first of two segments are as follows:
Date: June 27, 2015
Start Time: 5:15pm ET
Network: ABC Radio | Cumulus | WABC 77
Station: 770AM, 77WABC Radio
Show: “Living Better with Laura Smith”
Host: Laura Smith
About Host Laura Smith
As a music personality in New York for many years and host of her own national radio show, "Above and Beyond" on Sirius Satellite Radio, Laura Smith is passionate about all the things New York and all things radio! Now, Laura hosts “Living Better with Laura Smith”, an hour of lively discussion, “how to”, and various topics that will improve and impact the lives of our loyal listeners on 77WABC!
About AxoGen, Inc.
AxoGen (NASDAQ: AXGN) is a leading medical technology company dedicated to peripheral nerve repair. AxoGen’s portfolio of regenerative medicine products is available in the United States, Canada and several European countries and includes Avance® Nerve Graft, the only off-the-shelf commercially available processed nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site, AxoGuard® Nerve Connector, a porcine submucosa extracellular matrix (“ECM”) coaptation aid for tensionless repair of severed nerves, and AxoGuard® Nerve Protector, a porcine submucosa ECM product used to wrap and protect injured peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments.
To learn more about AxoGen and to sign up for news alerts, visit www.AxoGenInc.com.
Cautionary Statement Concerning Forward-Looking Statements
This Press Release contains "forward-looking" statements as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations or predictions of future conditions, events or results based on various assumptions and management's estimates of trends and economic factors in the markets in which we are active, as well as our business plans. Words such as "expects", "anticipates", "intends", "plans", "believes", "seeks", "estimates", "projects", "forecasts", "continue", "may", "should", "will" variations of such words and similar expressions are intended to identify such forward-looking statements. The forward-looking statements may include, without limitation, statements regarding our growth, our product development and product potential. The forward-looking statements are subject to risks and uncertainties, which may cause results to differ materially from those set forth in the statements. Forward-looking statements in this release should be evaluated together with the many uncertainties that affect AxoGen's business and its market, particularly those discussed in the risk factors and cautionary statements in AxoGen's filings with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and actual results may differ materially from those projected. The forward-looking statements are representative only as of the date they are made, and, except as required by law, AxoGen assumes no responsibility to update any forward-looking statements, whether as a result of new information, future events or otherwise.
Released June 26, 2015